Results of the SURMOUNT-5 trial (ClinicalTrials.gov Identifier:NCT05822830), which evaluated the efficacy and safety of tirzepatide (dual GIP/GLP-1 RA) compared with semaglutide (GLP-1 RA) in adults with obesity or overweight, at least one weight-related comorbidity but no T2D, are in process and expected to be presented and published in 2025. This evidence concerns the gene GCG and obesity disorder.